UGT1A1*28
|
CRC
|
UGT1A1*28
|
CRC
|
capecitabine + irinotecan Sensitive: B - Late Trials
|
capecitabine + irinotecan Sensitive: B - Late Trials
|
UGT1A1*28
|
CRC
|
UGT1A1*28
|
CRC
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
bevacizumab Sensitive: C2 – Inclusion Criteria
|
UGT1A1*28
|
NSCLC
|
UGT1A1*28
|
NSCLC
|
irinotecan Sensitive: C3 – Early Trials
|
irinotecan Sensitive: C3 – Early Trials
|